Frank Boess

4.7k total citations · 1 hit paper
45 papers, 3.0k citations indexed

About

Frank Boess is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Frank Boess has authored 45 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 18 papers in Cellular and Molecular Neuroscience and 8 papers in Organic Chemistry. Recurrent topics in Frank Boess's work include Receptor Mechanisms and Signaling (12 papers), Neurotransmitter Receptor Influence on Behavior (12 papers) and Nicotinic Acetylcholine Receptors Study (11 papers). Frank Boess is often cited by papers focused on Receptor Mechanisms and Signaling (12 papers), Neurotransmitter Receptor Influence on Behavior (12 papers) and Nicotinic Acetylcholine Receptors Study (11 papers). Frank Boess collaborates with scholars based in Switzerland, Germany and United Kingdom. Frank Boess's co-authors include Ian L. Martin, Viktor Lakics, Eric Karran, Andrew J. Sleight, Anne Bourson, Michael Bös, Rudy Schreiber, Jos Prickaerts, Martin Hendrix and F. Josef van der Staay and has published in prestigious journals such as Neurology, Annals of the New York Academy of Sciences and Journal of Neurochemistry.

In The Last Decade

Frank Boess

45 papers receiving 2.9k citations

Hit Papers

Molecular biology of 5-HT receptors 1994 2026 2004 2015 1994 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank Boess Switzerland 24 1.9k 1.4k 658 354 335 45 3.0k
Douglas W. Bonhaus United States 31 1.6k 0.9× 2.2k 1.6× 477 0.7× 622 1.8× 292 0.9× 78 3.6k
Xavier Langlois Belgium 38 2.1k 1.1× 2.3k 1.7× 435 0.7× 510 1.4× 212 0.6× 104 4.2k
Malcolm J. Sheardown Denmark 32 2.6k 1.4× 2.8k 2.0× 300 0.5× 414 1.2× 279 0.8× 82 4.1k
Eric S. Nisenbaum United States 32 1.5k 0.8× 2.4k 1.7× 309 0.5× 403 1.1× 117 0.3× 75 3.3k
Mark A. Varney United States 34 2.3k 1.2× 3.5k 2.5× 395 0.6× 614 1.7× 246 0.7× 85 4.6k
László G. Hársing Hungary 30 1.2k 0.6× 1.6k 1.2× 224 0.3× 311 0.9× 138 0.4× 138 2.7k
Ana Garcı́a-Osta Spain 31 1.9k 1.0× 794 0.6× 803 1.2× 989 2.8× 186 0.6× 59 3.4k
Lori L. McMahon United States 34 1.5k 0.8× 1.8k 1.3× 305 0.5× 481 1.4× 128 0.4× 80 3.4k
Michael P. Johnson United States 25 1.1k 0.6× 1.8k 1.3× 364 0.6× 260 0.7× 164 0.5× 52 2.6k
Ernesto Fedele Italy 36 1.5k 0.8× 1.5k 1.1× 587 0.9× 847 2.4× 95 0.3× 105 3.6k

Countries citing papers authored by Frank Boess

Since Specialization
Citations

This map shows the geographic impact of Frank Boess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Boess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Boess more than expected).

Fields of papers citing papers by Frank Boess

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Boess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Boess. The network helps show where Frank Boess may publish in the future.

Co-authorship network of co-authors of Frank Boess

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Boess. A scholar is included among the top collaborators of Frank Boess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Boess. Frank Boess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boess, Frank, Marzia A. Scelsi, Timo Grimmer, et al.. (2024). At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. The Journal of Prevention of Alzheimer s Disease. 11(3). 537–548. 1 indexed citations
2.
Jankovic, Joseph, Ira Goodman, Beth Safirstein, et al.. (2018). Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease. JAMA Neurology. 75(10). 1206–1206. 224 indexed citations
3.
Taylor, Kirsten I., Fabio Sambataro, Frank Boess, Alessandro Bertolino, & Juergen Dukart. (2018). Progressive Decline in Gray and White Matter Integrity in de novo Parkinson’s Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data. Frontiers in Aging Neuroscience. 10. 318–318. 60 indexed citations
4.
Buvat, Irène, Dimitrios Hatzichristou, Frank Boess, et al.. (2014). Continuation and effectiveness of tadalafil once daily during a 6‐month observational study in erectile dysfunction: the EDATE study. International Journal of Clinical Practice. 68(9). 1087–1099. 16 indexed citations
5.
Hatzimouratidis, Konstantinos, Irène Buvat, Hartwig Büttner, et al.. (2014). Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. International Journal of Impotence Research. 26(6). 223–229. 11 indexed citations
6.
Buvat, Irène, Hartwig Büttner, Konstantinos Hatzimouratidis, et al.. (2013). Adherence to Initial PDE5 Inhibitor Treatment: Randomized OpenLabel Study Comparing Tadalafil Once a Day, Tadalafil on Demand, and Sildenafil on Demand in Patients with Erectile Dysfunction. The Journal of Sexual Medicine. 10(6). 1592–1602. 28 indexed citations
7.
Wilhelm, Stefan, Frank Boess, Ulrich Hegerl, et al.. (2012). Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?. Expert Opinion on Drug Safety. 11(5). 699–711. 1 indexed citations
8.
Lakics, Viktor, Eric Karran, & Frank Boess. (2010). Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 59(6). 367–374. 365 indexed citations
9.
Blokland, Arjan & Frank Boess. (2008). Use of behavioural and long-term potentiation models in the development of memory-improving drugs. Expert Opinion on Drug Discovery. 3(9). 1067–1080. 3 indexed citations
10.
Boess, Frank, Martin Hendrix, F. Josef van der Staay, et al.. (2004). Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 47(7). 1081–1092. 251 indexed citations
11.
Steward, Lucinda J., et al.. (2000). Importance of Phenylalanine 107 in Agonist Recognition by the 5-Hydroxytryptamine3A Receptor. Molecular Pharmacology. 57(6). 1249–1255. 38 indexed citations
12.
Sleight, Andrew J., Frank Boess, Michael Bös, & Anne Bourson. (1998). The Putative 5‐ht6 Receptor: Localization and Function. Annals of the New York Academy of Sciences. 861(1). 91–96. 34 indexed citations
13.
Sleight, Andrew J., Frank Boess, Michael Bös, et al.. (1998). Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors. British Journal of Pharmacology. 124(3). 556–562. 150 indexed citations
14.
Sleight, Andrew J., Frank Boess, Anne Bourson, David R. Sibley, & Frederick J. Monsma. (1997). 5-HT 6 and 5-HT 7 Receptors: Molecular Biology, Functional Correlates and Possible Therapeutic Indications.. Drug News & Perspectives. 10(4). 214–224. 12 indexed citations
15.
Boess, Frank, et al.. (1997). Interaction of Tryptamine and Ergoline Compounds with Threonine 196 in the Ligand Binding Site of the 5-Hydroxytryptamine6 Receptor. Molecular Pharmacology. 52(3). 515–523. 29 indexed citations
16.
Bourson, Anne, et al.. (1997). Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice. Naunyn-Schmiedeberg s Archives of Pharmacology. 356(6). 820–826. 48 indexed citations
17.
Boess, Frank, et al.. (1997). Functional and Radioligand Binding Characterization of Rat 5-HT 6 Receptors Stably Expressed in HEK293 Cells. Neuropharmacology. 36(4-5). 713–720. 74 indexed citations
18.
Sleight, Andrew J., Frank Boess, Frederick J. Monsma, & Anne Bourson. (1996). 5-HT6 and 5-HT7 receptors: New targets for neuropsychiatry. European Neuropsychopharmacology. 6. S4–42. 2 indexed citations
19.
Boess, Frank, Sarah C. R. Lummis, & Ian L. Martin. (1992). Molecular Properties of 5‐Hydroxytryptamine3 Receptor‐Type Binding Sites Purified from NG1O8‐15 Cells. Journal of Neurochemistry. 59(5). 1692–1701. 29 indexed citations
20.
Boess, Frank & Ian L. Martin. (1992). Purification and characterisation of 5-HT3 receptors from NG108–15 neuroblastoma x glioma cells. Biochemical Society Transactions. 20(2). 217S–217S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026